• INVESTOR RELATIONS
    • Investor relations (NASDAQ)
    • Stock Information
    • Corporate Governance
    • Events & Presentations
    • Financials & Filings
    • Investor Resources
    • Email Alerts
    • News and Media
    • Investor relations (HKEX)
  • CONTACT US
  • 中文
  • WHO WE ARE
    • ABOUT Zai Lab
    • EXECUTIVE TEAM
    • BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD
    • OUR MISSION
  • WHAT WE DO
    • DISCOVERY
    • DEVELOPMENT
    • MANUFACTURING
    • COMMERCIALIZATION
    • PARTNERING
  • OUR R&D
    • PIPELINE
    • SELECTED ONGOING CLINICAL TRIALS
  • PRODUCTS
  • CAREERS
    • WORKING AT Zai Lab
    • JOIN US
  • NEWS
    • PRESS RELEASE
    • PARTNER NEWS
    • MEDIA REPORTS
Back to Pipeline

Odronextamab (CD20xCD3)

Prev: Ripretinib (KIT, PDGFRα)
Repotrectinib (ROS1, TRK) :Next
沪公网安备 31011502016519号   沪ICP备19002390号-1

Copyright @ 2019 Zai Lab All Rights Reserved.